University of Havana
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From University of Havana
It ought to be hard to convince an oncology-focused biotech to license its crown jewel to a firm without experience developing oncology drugs, but Serono SA was able to do just that-twice in the span of eight days-when it in-licensed Phase II and Phase III oncology programs, respectively, from Micromet AG and CancerVax Corp. in December.
Summarizing the month in European dealmaking.
- Academic and Research Institutions